Tuberculosis (TB) is a potentially serious infectious disease that primarily affects the lungs, often referred to as the 'silent killer'. Despite being preventable and curable, TB remains a major global health problem, largely due to challenges in early detection. This article provides an overview of modern diagnostic approaches for TB.
The GeneXpert MTB/RIF is a revolutionary diagnostic tool that provides results within two hours. It detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampicin (RIF), a primary drug used to treat TB. The high sensitivity and specificity of this test make it a crucial tool in TB management, especially in settings with high HIV prevalence.
Line Probe Assays (LPAs) are molecular techniques that detect both TB and drug resistance. LPAs allow for rapid detection of resistance to first and second-line drugs, crucial in the management of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).
Liquid culture systems are the gold standard for TB diagnosis. They provide definitive diagnosis and drug susceptibility testing (DST), although they require several weeks to yield results. Modern systems like the MGIT 960 have improved turnaround times and increased detection rates.
CT scanning is a non-invasive imaging technique used to detect pulmonary abnormalities indicative of TB. It is particularly useful in diagnosing extrapulmonary TB and TB in children, where traditional diagnostic methods may be less effective.
Early and accurate diagnosis of TB is critical to reducing its global burden. While no single diagnostic tool is perfect, the combined use of these modern techniques can greatly improve the detection and management of TB. Continued research and development in this field are essential to unmask this silent killer.
1.
Race, Geography Linked to Gaps in Prostate Cancer Care
2.
Sports for girls are frequently abandoned due to uniform issues.
3.
According to the Lancet, having cancer and VTE at the same time increases mortality risk.
4.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Hematopoietic Clonal Competition in Blood Disorders
2.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
3.
Developmental Iron Biology Beyond Infancy: Mechanisms, Clinical Implications, and Emerging Directions
4.
Next-Generation Bone Marrow Harvest Technologies
5.
Strategic Applications in Hematology in Clinical Decision-Making
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Understanding the Common Causes of Anemia
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation